metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Serum cytokines in childhood-Takayasu arteritis: Are they biomarkers for indolen...
Información de la revista
Vol. 78.
(enero - diciembre 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 78.
(enero - diciembre 2023)
Comments
Acceso a texto completo
Serum cytokines in childhood-Takayasu arteritis: Are they biomarkers for indolent disease activity?
Visitas
776
Gleice Clementea,
Autor para correspondencia
gleice.clemente@outlook.com

Corresponding author.
, Maria Teresa Terreria, Rosa M.R. Pereirab, Bruno Gualanob, Clovis Artur Silvac, Alexandre Wagner de Souzad
a Pediatric Rheumatology Unit, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil
b Division of Rheumatology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
c Pediatric Rheumatology Unit, Children and Adolescents Institute, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
d Division of Rheumatology, Department of Medicine, Universidade Federal de São Paulo, São Paulo, SP, Brazil
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Cytokine levels of childhood-onset Takayasu arteritis patients and healthy controls.
Texto completo

Childhood onset-Takayasu Arteritis (c-TA) is a chronic and recurrent disease, where arterial lesions may progress even in patients in apparent disease remission. To date, there is no gold standard for assessing disease activity in c-TA, making clinical evaluation of c-TA patients a challenge.

Research about valid biomarkers for disease activity in TA has been published during the last few decades, however, there are dissimilarities among the results.1 Furthermore, c-TA seems to be different than in adults, with a more pronounced inflammation and more systemic symptoms, such as fever and fatigue, at the beginning of the disease.2

It is worth noting that there is a paucity of studies assessing disease activity parameters in c-TA. The aim of this study was to assess the levels of serum cytokines in c-TA patients in order to find a valid biomarker for indolent disease in patients in remission by clinical scores.

This is a cross-sectional study, which included c-TA patients from three Brazilian reference centers in Pediatric Rheumatology. Inclusion criteria were a fulfillment of EULAR/PRINTO/PRES c-TA classification criteria and being in clinical remission according to the Indian Takayasu Clinical Activity Score (ITAS) 2010 and Pediatric Vasculitis Activity Score (PVAS).3–5 Immunosuppressive drugs were withdrawn during two half-lifetime periods before blood collection. Fourteen Healthy Controls (HC), age and sex-matched, were included.

Assessment of the following serum cytokines was performed: Interleukin-1 receptor antagonist (IL-1ra), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Interleukin-12p70 (IL-12p70), Tumor Necrosis Factor Alpha (TNF-α), Interferon Gamma (IFN-γ), Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF).

Twelve c-TA patients were evaluated (66.7% girls). The mean age was 18.7±2.84 years, and the median time between disease onset and the diagnosis was 11.5 (5.0‒25.5) months. The median follow-up time of c-TA patients was 10 (7.0‒11.8) years. All patients were on medication: 7 (58%) were on biological Disease-Modifying Antirheumatic Drugs (DMARDs) (i.e., 4 on infliximab, 2 on adalimumab, and 1 on tocilizumab) combined with conventional DMARDs.

Serum cytokine levels presented no differences between c-TA patients and HC (p > 0.05) (Table 1). When the extension of the disease was assessed, diffuse arterial involvement (represented by angiographic type V Hata classification) and localized disease (represented by angiographic types I, IIa, and III Hata classification) revealed no differences in cytokine levels.6

Table 1.

Cytokine levels of childhood-onset Takayasu arteritis patients and healthy controls.

Laboratory Markers  Patients (N = 12)  Controls (N = 14)  p-value 
IFN-γ (pg/mL)  2.3 (1.4‒8.7)  1.3 (0.9‒2.2)  0.089 
IL-10 (pg/mL)  9.4 (4.5‒13.4)  7.4 (4.5‒10.2)  0.410 
IL-12p70 (pg/mL)  3.5 (2.6‒9.6)  4.9 (3.2‒5.2)  0.502 
IL-1ra (pg/mL)  41.6 (32.9‒62.3)  39.8 (21.5‒43.7)  0.135 
IL1-β (pg/mL)  2.1 (1.6‒3.3)  2.1 (1.9‒2.6)  0.757 
IL-6 (pg/mL)  8.0 (3.6‒27.0)  9.2 (2.6‒14.8)  0.607 
TNF-α (pg/mL)  13.7 (6.8)  13.8 (6.5)  0.969 
VEGF (pg/mL)  1.9 (1.1‒2.6)  1.5 (1.4‒2.0)  0.440 
PDGF (pg/mL)  44.2 (31.2‒674.7)  130.8 (53.9‒1010.7)  0.446 

IFN, Interferon; IL, Interleukin; N, Number of participants; PDGF, Platelet-Derived Growth Factor; TNF, Tumor Necrosis Factor; VEGF, Vascular Endothelial Growth Factor. Results are presented as mean and standard deviation or as median and interquartile range.

Progression of arterial lesions in TA is observed in a significant number of patients even during immunosuppressive therapy. Therefore, it is of paramount importance to identify surrogate markers indicating smoldering arterial inflammation, despite therapy, in order to escalate treatment.

It is speculated that multiple pathological processes are involved in TA, though a clear pathogenesis has not yet been established. In a previous study from the group using 18F-Fluordeoxiglucose ‒ Positron Emission Tomography/Magnetic Resonance Imaging (FDG-PET/MRI) in c-TA, 10 of 12 patients presented high arterial FDG-uptake (visual score = 3), despite undergoing treatment and apparent clinical remission.7 This finding reinforces the need to seek out a reliable biomarker that could reflect smoldering disease activity.

In this study, serum cytokine levels were similar between c-TA patients in clinical remission and HC. Of note, the patients had long periods of follow-up and were on long-term immunosuppressants. Studies with adult TA revealed that plasma/serum cytokine levels were not useful to differentiate patients in active disease and in remission, especially when using anti-cytokine therapy.8,9 The same results regarding cytokine levels were found in other studies between TA patients and HC.10

In conclusion, the search for reliable biomarkers to identify indolent disease activity is also a challenge in c-TA patients. Further prospective and multicenter studies are needed in order to improve the study of biomarkers involved in indolent vascular inflammation during the follow-up of c-TA patients.

Compliance with ethical standards

This study was approved by the local Institutional Review Boards. The patients were included only after the signature of their informed consent and assent.

References
[1]
B Savioli, WH Abdulahad, E Brouwer, CGM Kallenberg, AWS. De Souza.
Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?.
Autoimmun Rev, 16 (2017), pp. 1071-1078
[2]
G Clemente, MO Hilário, H Lederman, CA Silva, AM Sallum, LM Campos, et al.
Takayasu arteritis in a Brazilian multicenter study: children with a longer diagnosis delay than adolescents.
Clin Exp Rheumatol, 32 (2014), pp. 128-133
[3]
S Ozen, A Pistorio, SM Iusan, A Bakkaloglu, T Herlin, R Brik, et al.
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu's arteritis: Ankara 2008. Part II: final classification criteria.
Ann Rheum Dis, 69 (2010), pp. 798-806
[4]
S Fritschi, RM Copes, B Savioli, MF Aguiar, RM Ciconelli, VF Azevedo, et al.
Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language.
Adv Rheumatol, 59 (2019), pp. 43
[5]
P Dolezalova, Price-Kuehne Fe, S Özen, SM Benseler, DA Cabral, J S Anton, et al.
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).
Ann Rheum Dis, 72 (2013), pp. 1628-1633
[6]
A Hata, M Noda, R Moriwaki, F. Numano.
Angiographic findings of Takayasu arteritis: new classification.
Int J Cardiol, 54 (1996), pp. S155-S163
[7]
G Clemente, RMR Pereira, N Aikawa, CA Silva, LMA Campos, G Alves, et al.
Is positron emission tomography/magnetic resonance imaging a reliable tool for detecting vascular activity in treated childhood-onset Takayasu's arteritis? A multicentre study.
Rheumatology, 61 (2022), pp. 554-562
[8]
L Pulsatelli, L Boiardi, E Assirelli, G Pazzola, F Muratore, O Addimanda, et al.
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study.
Clin Exp Rheumatol, 35 (2017), pp. S102-S110
[9]
E Tombetti, MC DI Chio, S Sartorelli, M Papa, A Salerno, B Bottazzi, et al.
Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis.
Arthritis Res Ther, 16 (2014), pp. 479
[10]
B Savioli, BR Salu, MV De Brito, ML Vilela Oliva, AWS De Souza.
Silent arterial inflammation during the apparent remission state of Takayasu's arteritis. What do cytokines tell us?.
Clin Exp Rheumatol, 36 (2018), pp. 33-39

In Memoriam.

Copyright © 2023. HCFMUSP
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos